DIN 02491796 — NAT-GEFITINIB 250 MG
NAT-GEFITINIB is a tablet of Gefitinib marketed by NATCO PHARMA (CANADA) INC. The full Gefitinib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02491796
- Brand name
- NAT-GEFITINIB
- Active ingredient
- Gefitinib
- Strength
- 250 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- NATCO PHARMA (CANADA) INC
- Health Canada status
- DORMANT
- Drug class
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Gefitinib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02468050 | APO-GEFITINIB | 250 MG | TABLET | APOTEX INC | MARKETED |
| 02248676 | IRESSA | 250 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED |
| 02500663 | JAMP GEFITINIB | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |